The FDA granted MRTP orders for 20 Zyn nicotine pouch variants, authorizing PMI to market them as lower risk for cancer, heart disease and lung disease. Zyn, acquired through Swedish Match, is PMI’s fastest-growing smoke-free franchise and can now feature FDA-approved health claims in advertising and packaging.
The FDA issued Modified Risk Tobacco Product orders for 20 Zyn nicotine pouch variants, marking the first time any nicotine pouch has received such clearance; the authorization permits explicit labeling of reduced risks for cancer, heart disease, stroke, emphysema and chronic bronchitis compared with cigarettes.
Zyn, acquired through the Swedish Match deal, represents PMI’s fastest-growing consumer franchise and underpins its smoke-free product pivot; clinical data show over 50% of adult smokers using Zyn quit cigarettes entirely within 30 days, while 80.7% reduced their daily cigarette intake after switching.
A PMI U.S. survey found that 86% of Americans favor innovations that solve everyday problems over headline-grabbing projects, 77% view much current innovation as hype rather than impact, and 90% expect companies to engage local communities as partners for meaningful solutions.
Finviz
